Molika Ashford

The analytical validity study is the first published featuring full performance data for the firm's Personalized Cancer Monitoring technology.

The company is collecting the data necessary to add at least two other drugs to its current TNFi response predictor, which it believes will accelerate adoption.

Recent meeting presentations have offered a first look at the company's targeted methylation approach and the test's high sensitivity in early-stage cancers.

The method, called GEMINI, improved detection of both overall cancer and the earliest-stage cancers when added to the firm's existing platform.

The company performed nearly 32,000 tests during the quarter, a 28 percent increase over the same period of 2022, with Decipher and Afirma assays driving the growth.

The company beat expectations on the top and bottom lines in the second quarter, primarily driven by growth in clinical oncology testing, and upped its full-year revenue guidance.

Despite recent reimbursement struggles, the company said it was raising its full-year guidance above its previously estimated $170 million to $180 million.

The company said it expects to launch a first version of its residual cancer test, OncoDetect, by the end of this year, while ongoing studies explore newer technology.

The company is hoping to bring a blood-based screening test to the clinic after publishing promising results on its novel 18-RNA signature.

Investigators hope they can establish the technology in kidney cancer and other tumor types to improve surgery success and associated survival outcomes.